Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Silence Therapeutics Plc ADR
(NQ:
SLN
)
21.62
-0.65 (-2.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
324,153
Open
22.23
Bid (Size)
16.00 (1)
Ask (Size)
23.08 (1)
Prev. Close
22.27
Today's Range
21.50 - 22.30
52wk Range
4.600 - 27.72
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock
April 22, 2024
Via
Benzinga
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
April 11, 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Via
InvestorPlace
Performance
YTD
+16.55%
+16.55%
1 Month
+0.14%
+0.14%
3 Month
+13.79%
+13.79%
6 Month
+207.54%
+207.54%
1 Year
+341.22%
+341.22%
More News
Read More
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
April 08, 2024
From
Silence Therapeutics plc
Via
Business Wire
7 Biotech Stocks Ready to Ride the Sector’s Resurgence
March 18, 2024
Via
InvestorPlace
What 4 Analyst Ratings Have To Say About Silence Therapeutics
March 13, 2024
Via
Benzinga
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
March 14, 2024
Via
Benzinga
What's Going On With Silence Therapeutics Stock Today?
March 13, 2024
Via
Benzinga
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
March 13, 2024
From
Silence Therapeutics plc
Via
Business Wire
Earnings Scheduled For March 13, 2024
March 13, 2024
Via
Benzinga
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024
February 28, 2024
From
Silence Therapeutics plc
Via
Business Wire
Earnings Scheduled For March 12, 2024
March 12, 2024
Via
Benzinga
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial
February 23, 2024
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
February 05, 2024
From
Silence Therapeutics plc
Via
Business Wire
Boeing Posts Upbeat Results, Joins Stryker, Automatic Data Processing And Other Big Stocks Moving Higher On Wednesday
January 31, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
Silence Therapeutics plc
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 13, 2023
Via
Benzinga
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
December 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 08, 2023
From
Silence Therapeutics plc
Via
Business Wire
Is This A Miracle Drug For 'Sticky Cholesterol'? Analysts Applaud Safety, Efficacy Of Silence Therapeutics' Heart Disease Candidate
November 01, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 01, 2023
Via
Benzinga
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease
November 01, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
September 26, 2023
From
Silence Therapeutics plc
Via
Business Wire
Silence Therapeutics to Participate in September Investor Conferences
September 06, 2023
From
Silence Therapeutics plc
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.